Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹306.20down ₹9.15 (2.90%)BSE ₹306.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹315.35.
30 Oct: open ₹317.00, high ₹317.35, low ₹304.90
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,876 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,10,63344.3% delivered
Marksans Pharma share news and announcements
683 announcements, routine notices left out, newest first. Page 13 of 14.
May 2011
4 May · Management
Board of Directors of the Company at its meeting held on May 02, 2011, has appointed Mr. Ajoy S. Joshi as a Director (non-executive and independent) of the Company to fill the casual vacancy caused by the resignation of Mr. Kumar Nair effective from May 02, 2011.3 May · Results
Company will publish Annual Audited Results for the year ended March 31, 2011 before May 30, 2011. Therefore, unaudited financial results for the quarter ended on March 31, 2011 will not be published.3 May · Management
Board of Directors of the Company has, at its meeting held on May 02, 2011, appointed Mr. Ajoy S. Joshi as a Director (non-executive and independent) of the Company to fill the casual vacancy caused by the resignation of Mr. Kumar Nair effective from May 02, 2011.
Feb 2011
7 Feb · Board meeting
To consider and approve Unaudited Financial Results for the Quarter ended on December 31, 2010.
Dec 2010
15 Dec · Address Change
Registered Office of the Company has changed from "21st Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai - 400053" to "11th Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai - 400053" with effect from December 14, 2010.
Nov 2010
25 Nov · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended September 30,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Nov · Management
Mr. Kumar Nair has resigned as a Director of the Company effective from November 02, 2010.3 Nov · Board meeting
To consider and approve Unaudited Financial Results for the Quarter ended on September 30, 2010.
Oct 2010
Sep 2010
2 Sep · Meeting
Company has announced the book closure from September 24, 2010 to September 28, 2010 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on September 28, 2010.
Aug 2010
19 Aug · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2010
30 Jul · Board meeting
To consider and approve :- (1) Annual Audited Financial Results for the Year ended March 31, 2010, and (2) Unaudited Financial Results for the Quarter ended on June 30, 2010.29 Jul · Updates
Pursuant to the resolution passed by the Shareholders of the Company through voting by postal ballot which was announced on 2nd February, 2010, the Company has entered into a Business Transfer Agreement on 28th July, 2010 with Kores (India) Limited for sale and transfer of its Active Pharmaceutical Ingredient (API) business together with the manufacturing facilities located at Plot No. A88 & Plot No. D10, M.I.D.C., Village - Kurkumbh, Tal - Daund, Dist. Pune, Maharashtra as a going concern on the terms and conditions as set out in the said Business Transfer Agreement. After hiving off the API business, the Company intends to focus more on the International formulation business which has tremendous growth potentials.
May 2010
21 May · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the period ended March 31,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2010
19 Apr · Board meeting
To consider and approve Unaudited Financial Results for the quarter ended March 31, 2010.15 Apr · Conversion of FCCBs
Conversion of Foreign Currency Convertible Bonds into equity shares. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
4 Mar · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the period ended December 31,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
3 Feb · Results
As per the result of the postal ballot announced on February 02, 2010 the shareholders have approved both the following resolutions, as set out in the notice dated December 29, 2009, with requisite majority: (1) An Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956 relating to sale, lease or otherwise disposal of the API Plants of the Company located at Plot No. A88 & D10, Kurkumbh, MIDC, Pune, and (2) A Special Resolution under Section 81(1A) of the Companies Act, 1956 relating to raising of capital through issue of equity shares and/or equity shares through depository receipts and/or foreign currency convertible bonds and/or any other convertible bonds/securities upto an amount not exceeding USD125 Million.
Jan 2010
15 Jan · Board meeting
Meeting on 29 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”7 Jan · Meeting
Pursuant to Section 192A (2) of the Companies Act, 1956 read with the Companies (passing of the Resolution by Postal Ballot) Rules, 2001, for passing the following resolutions: Item No. 1: Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956 for sale, lease or otherwise disposal of the Company's API plants located at Plot No.A88 & D10, Kurkumbh MIDC, Pune.(2) Special Resolution under Section 81(1A) of the Companies Act, 1956 for issue of Equity shares and/or Equity Shares through depository receipts and/or Foreign Currency Convertible Bonds/Securities up to an amount not exceeding USD 125 million. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
29 Dec · Board meeting
Board of Directors of the Company, at its meeting held on December 29, 2009, has decided to conduct postal ballot to seek approval of the members of the Company: (1) To sell/lease/dispose the Active Pharmaceutical Ingredient (API) plants of the Company located at Plot No. A88 & D10, Kurkumbh, MIDC, Pune, by way of an Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956, and; (2) To raise capital through issue of equity shares and/or equity shares through depository receipts and/or foreign currency convertible bonds and/or any other convertible bonds/securities upto an amount not exceeding USD 125 Million by way of a Special Resolution under Section 81(1A) of the Companies Act, 1956.28 Dec · Board meeting
To consider and approve conduct of postal ballot to seek approval of the members of the Company: (1) To sell/lease/dispose the Active Pharmaceutical Ingredient (API) plants of the Company located at Plot No. A88 & D10, Kurkumbh, MIDC, Pune, by way of an Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956, and; (2) To raise capital through issue of equity shares and/or equity shares through depository receipts and/or foreign currency convertible bonds and/or any other convertible bonds/securities upto an amount not exceeding USD 125 Million by way of a Special Resolution under Section 81(1A) of the Companies Act, 1956.2 Dec · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended September 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
30 Oct · Raising of capital/Others
Board of Directors of the Company at its meeting held on October 30, 2009 has taken following decisions, subject to other approvals whenever necessary and the prevailing market condition: 1) To restructure business model of the Company/ having off API division of the Company and to focus more on the Global Formulation business, and 2) To raise capital through issue of equity or equity linked instruments upto Rs. 200 Crores.9 Oct · Board meeting
Meeting on 30 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Sep 2009
30 Sep · Meeting
Proceedings of the Annual General Meeting of the Company held on September 25, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Sep · Retirement
Dr. Kim Tan, Director of the Company, has retired (retirement by rotation) as a Director of the Company with effect from September 25, 2009 i.e. the date of the Annual General Meeting of the Company.8 Sep · Meeting
Company has announced the book closure from September 21, 2009 to September 25, 2009 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on September 25, 2009.2 Sep · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
21 Jul · Business
Press release dated July 21, 2009, titled "Marksans Pharma Limited announces USFDA approval of generic Ibuprofen Capsules (Liquid Filled), 200 mg for Advil Liqui-Gels 200mg". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Jul · Board meeting
Meeting on 31 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Jun 2009
15 Jun · Board meeting
To consider and approve the Annual Audited Financial Results for the year ended March 31, 2009.
Apr 2009
21 Apr · Results
Company will publish Annual Audited Results for the year ended March 31, 2009 before June 30, 2009. Therefore, unaudited financial results for the quarter ended on March 31, 2009 will not be published or given to Stock Exchanges.
Feb 2009
20 Feb · Change in Company Secretary
Mr. Hitesh Kannai, Company Secretary and Manager-Legal has resigned from the service of the Company effective from January 30, 2009 and accordingly has also ceased as the Compliance Officer. Further, Mr. Harshavardhan Panigrahi has been appointed as the new Company Secretary and Manager-Legal of the Company with effect from February 16, 2009. He has also been designated as the Compliance Officer.
Jan 2009
20 Jan · Board meeting
To consider the following business: 1) To take on records Un-audited (Provisional) quarterly results for the quarter ended December 31, 2008; 2) Any other business with the permission of the Chair.
Nov 2008
3 Nov · Updates
Company has received Certificate of suitability for Ranitidine Hydrochloride drug substance from the European directorate for the Quality of Medicines and Healthcare (EDQM). With the grant of this Certificate of Suitability for Ranitidine Hydrochloride drug substance by EDQM, the doors of European markets have opened for access for the Company's API business. It is a significant achievement as the Company is focusing on the Regulated Market for its growth. Companies recently acquired subsidiary M/S. RelonChem Limited, also markets Ranitidine formulation into the regulated markets of Europe / U.K. This Certificate is recognized by 35 signatory states of the European Pharmacopoeia Convention and by the European Union. Other Countries have also chosen to recognize them. This Certificate of Suitability can be used by the manufacturers of pharmaceutical products in their applications for marketing authorization to demonstrate the compliance of the drug substance used with the official monograph of European Pharmacopoeia.
Oct 2008
20 Oct · Board meeting
To consider the following business : 1) To take on record Un-audited (Provisional) quarterly results for the quarter ended September 30, 2008. 2) Any other business with the permission of the Chair.
Sep 2008
29 Sep · Meeting
Outcome of Annual General Meeting held on September 29, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Sep · Board meeting
At the meeting of the Board of Directors of the Company held on September 23, 2008, it was decided to make allotment of 8400241 equity shares of Re. 1/- to M/s. Bamacle LLc on preferential allotment basis.15 Sep · Board meeting
Board Meeting scheduled to be held on September 16, 2008, to make allotment of 8400241 Equity shares of Re. 1/- to M/s. Bamacle LLc on preferential allotment basis, has been postponed to be held on September 23, 2008 to transact the same agenda.11 Sep · Meeting
At the Extra Ordinary General Meeting of the Members of the Company, held on September 10, 2008, members of the Company unanimously approved the special resolution under Section 81 (1) A of the companies Act, 1956, for allotment of 8400241 Equity Shares of Re. 1/- each, of the Company, to M/s. Barnacle LLC on preferential allotment basis.10 Sep · Meeting
Company has fixed September 25, 2008 to September 29, 2008 as Book Closure dates for the purpose of conducting Annual General Meeting on September 29, 2008.8 Sep · Board meeting
To make allotment of 8400241 Equity shares of Re. 1/- to M/s. Bamacle LLc on preferential allotment basis, if approved by the shareholders at the Extra Ordinary General Meeting to be held on September 10, 2008.4 Sep · Board meeting
At the meeting of the Board of Directors of the Company held on September 02, 2008 the following decisions were taken: (1) Adoption of Audited Annual Accounts of the Company for the year ended March 31, 2008, along with Auditors report, Directors report, Corporate Governance Report and management Analysis and Discussion report. (2) Appointment of Statutory Auditors of the Company subject to the approval of the members of the Company. (3) Approval of ESOP scheme for the employees of the Company. (4) Approval of the notice of the Annual General Meeting and fixation of the day, date, time and place of the Annual General Meeting. (5) Fixation of Book Closure dates for the purpose of the Annual General Meeting.
Aug 2008
28 Aug · Business
"Marksans Pharma Limited's subsidiary, Marksans Pharma (UK) Limited, has entered into a definitive agreement to acquire 100% of the share capital of RelonCehm Limited." The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Aug · Board meeting
To consider and adopt: 1) Audited Annual Accounts of the Company for the year ended March 31, 2008, along with Auditors report, Directors report, Corporate Governance Report and management Analysis and Discussion report. 2). To consider appointment of Statutory Auditors of the Company. 3). To consider and approve ESOP scheme for the employees of the Company. 4). To approve the draft of notice of the Annual General Meeting. 5). Fix the day, date, time and place of the Annual General Meeting. 6). To fix book Closure dates for the purpose of the Annual General Meeting. 7). Any other business with the permission of the Chair.19 Aug · Meeting
Notice of Extra Ordinary General Meeting of the members of the Company to be held on September 10, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Aug · Issue and allotment of shares
Board of Directors of the Company has at their meeting held on August 11, 2008 resolved to create, issue, offer and allot 84,00,241 Equity shares of Rs.1/- each at a premium of Rs. 19.12/- each, of the Company, aggregating to an amount not exceeding Rs. 16,89,87,000/- to Barnacle LLC, on the preferential allotment basis.